Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Merus (MRUS – Research Report) today and set a price target of $93.00. The company’s shares closed yesterday at $46.22.

In September 2024, Merus announced the first patient was dosed in LiGeR-HN1, a phase 3 trial evaluating the efficacy and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC ...

Feb. 27, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ®, Triclonics ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company ...

In September 2024, Merus announced the first patient was dosed in LiGeR-HN1, a phase 3 trial evaluating the efficacy and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m ...

TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET The webcasts of the presentations will be ...

If you’re on the fence about investing in Vericel Corporation or Merus N.V. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

DBS CEO Piyush Gupta said the bank will shrink its workforce by 10% in the next three years due to artificial intelligence replacing human roles. Listen to Story DBS to cut 4,000 jobs over three years ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific ...

Merus has a 1 year low of $37.77 and a 1 year high of $61.61. The company has a market capitalization of $3.20 billion, a P/E ratio of -11.84 and a beta of 1.11. A number of analysts have issued ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific ...

Singapore's biggest bank, DBS, says it expects to cut about 4,000 roles over the next three years as artificial intelligence (AI) takes on more work currently done by humans. The move will affect ...